<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02718378</url>
  </required_header>
  <id_info>
    <org_study_id>PR3107</org_study_id>
    <nct_id>NCT02718378</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Efficacy of Estetrol in Healthy Men</brief_title>
  <official_title>A Phase I, Double-blind, Randomised, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Multiple Dosages of Estetrol in Healthy Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pantarhei Oncology B.V.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pantarhei Oncology B.V.</source>
  <brief_summary>
    <textblock>
      The current study is designed as a phase Ib multiple dose study to evaluate the safety,&#xD;
      tolerability, pharmacokinetics and pharmacodynamics of E4 in healthy men after daily oral&#xD;
      administration for 28 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events (AEs)</measure>
    <time_frame>28 days</time_frame>
    <description>Changes from baseline measurements considered clinically significant by the Investigator will be reported as AEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in hormone levels</measure>
    <time_frame>28 days</time_frame>
    <description>The serum concentrations of Follicle Stimulating Hormone (FSH), Luteinising Hormone (LH), Estradiol (E2), total testosterone and free testosterone levels (actual values as well as percentage change from pre-dose concentration) will be listed and summarized descriptively by treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in haemostasis parameters</measure>
    <time_frame>28 days</time_frame>
    <description>The relative change in Activated Protein C (APC)-resistance, prothrombin factor 1 + 2, D-dimer, free Tissue Factor Pathway Inhibitor (TFPI), antothrombin activity, protein S activity and angiotensinogen levels and the actual change from baseline will be calculated by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in lipid parameters</measure>
    <time_frame>28 days</time_frame>
    <description>The relative change in total cholesterol, triglycerides, High Density Lipoprotein (HDL) cholesterol, Low Density Lipoprotein (LDL) cholesterol, Lipoprotein A (Lp(A)) levels and the actual change from baseline will be calculated by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glucose levels</measure>
    <time_frame>28 days</time_frame>
    <description>The relative change in glucose levels and the actual change from baseline will be calculated by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in bone turnover markers</measure>
    <time_frame>28 days</time_frame>
    <description>The relative change in osteocalcin, type I collagen telopeptide (CTX-1) and parathyroid hormone (PTH) and the actual change from baseline will be calculated by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sex-hormone binding globulin (SHBG) levels</measure>
    <time_frame>28 days</time_frame>
    <description>The relative change in SHBG levels and the actual change from baseline will be calculated by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic effect of estetrol</measure>
    <time_frame>28 days</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic effect of estetrol</measure>
    <time_frame>28 days</time_frame>
    <description>Terminal elimination half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic effect of estetrol</measure>
    <time_frame>28 days</time_frame>
    <description>Time to reach Cmax (tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic effect of estetrol</measure>
    <time_frame>28 days</time_frame>
    <description>Peak plasma concentration (Cmax)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>No added active</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo without estetrol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>estetrol dose level 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>estetrol given in dose level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>estetrol dose level 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>estetrol given in dose level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>estetrol dose level 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>estetrol given in dose level 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estetrol</intervention_name>
    <arm_group_label>estetrol dose level 1</arm_group_label>
    <arm_group_label>estetrol dose level 2</arm_group_label>
    <arm_group_label>estetrol dose level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>No added active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male, age between 40 and 70 years (both inclusive);&#xD;
&#xD;
          -  Good physical and mental health as judged by the Investigator determined by medical&#xD;
             history, physical examination (including prostate palpation), clinical laboratory,&#xD;
             vital signs and ECG recording;&#xD;
&#xD;
          -  Body mass index between ≥ 18.5 and ≤ 30.0 kg/m2;&#xD;
&#xD;
          -  Normal prostate-specific antigen (PSA) value (&lt; 3.0 ng/mL);&#xD;
&#xD;
          -  Non-vasectomized men must agree to use a condom with spermicide or abstain from sexual&#xD;
             intercourse during the study until 90 days beyond the last dose of study medication.&#xD;
             Men who have been vasectomized less than 4 months prior to study start must follow the&#xD;
             same restrictions as non-vasectomized men;&#xD;
&#xD;
          -  Men must agree not to donate sperm from the first dose until 90 days after the last&#xD;
             dose;&#xD;
&#xD;
          -  Ability to communicate well with the Investigator and to comply with the requirements&#xD;
             of the entire study;&#xD;
&#xD;
          -  Willing to give informed consent in writing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically significant abnormality following review of medical history, laboratory&#xD;
             results, physical examination and ECG at screening as judged by the Investigator;&#xD;
&#xD;
          -  Conditions or disorders that might affect the absorption, distribution, metabolism or&#xD;
             excretion of any of the study drugs;&#xD;
&#xD;
          -  Previous use of steroids within:&#xD;
&#xD;
               -  8 weeks for oral preparations&#xD;
&#xD;
               -  4 weeks for transdermal preparations&#xD;
&#xD;
               -  Any time for injections;&#xD;
&#xD;
          -  Contraindications for steroids or estetrol;&#xD;
&#xD;
          -  Prostate hyperplasia or micturition problems that suggest the presence of prostate&#xD;
             hyperplasia;&#xD;
&#xD;
          -  Presence of an active acute or chronic infection, including syphilis, HIV or viral&#xD;
             hepatitis B and/or C (or previously treated);&#xD;
&#xD;
          -  Treatment for any major psychiatric disorder in the previous 12 months or use of&#xD;
             antidepressant medication before screening;&#xD;
&#xD;
          -  Hypersensitivity to the active substances or to any of the excipients of the&#xD;
             investigational product or placebo therapy;&#xD;
&#xD;
          -  Use of probiotics (as present in dairy products, fortified foods etc.) during the 3&#xD;
             months before screening and during the clinical study;&#xD;
&#xD;
          -  Use of one or more of the following medications:&#xD;
&#xD;
               -  Antihypertensive drugs&#xD;
&#xD;
               -  Present use or use within 30 days before the start of the study drug of the&#xD;
                  following drugs: aprepitant, bosentan, armodafinil, phenytoin, barbiturates,&#xD;
                  primidone, carbamazepine, oxcarbazepine, glucocorticoids, topiramate, felbamate,&#xD;
                  rifampicin, clobazamechinacea; vemurafenib, non-nucleoside reverse transcriptase&#xD;
                  inhibitors, griseofulvin, ketoconazole, and herbal remedies containing Hypericum&#xD;
                  perforatum&#xD;
&#xD;
               -  Any medication (including over-the-counter products) within 14 days before first&#xD;
                  dosing except for occasional non-steroidal anti-inflammatory drugs (NSAIDs; e.g.&#xD;
                  ibuprofen); paracetamol is not permitted&#xD;
&#xD;
               -  Use of antibiotics;&#xD;
&#xD;
          -  Administration of any other investigational drug within 3 months before first dosing;&#xD;
&#xD;
          -  Loss of more than 400 mL blood during the 3 months before screening, e.g. as a blood&#xD;
             donor, or intention to donate blood in the 3 months after completing the study;&#xD;
&#xD;
          -  Subjects with a history of (within 12 months) alcohol or drug abuse or with a positive&#xD;
             result at screening, for tests of:&#xD;
&#xD;
               -  alcohol intake&#xD;
&#xD;
               -  drug abuse;&#xD;
&#xD;
          -  Currently smoking or smoked within the last 6 months before screening.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tjeert Mensinga, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>QPS Netherlands BV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QPS Netherlands BV</name>
      <address>
        <city>Groningen</city>
        <zip>9713 AG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Phillips I, Shah SI, Duong T, Abel P, Langley RE. Androgen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer. Oncol Hematol Rev. 2014 Spring;10(1):42-47.</citation>
    <PMID>24932461</PMID>
  </results_reference>
  <results_reference>
    <citation>Coelingh Bennink HJ, Holinka CF, Diczfalusy E. Estetrol review: profile and potential clinical applications. Climacteric. 2008;11 Suppl 1:47-58. doi: 10.1080/13697130802073425. Review.</citation>
    <PMID>18464023</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>February 18, 2016</study_first_submitted>
  <study_first_submitted_qc>March 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2016</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>randomized</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

